News & Updates

Show Multimedia Only

Venetoclax-azacitidine duo may benefit older patients with AML

24 Sep 2020 by

The addition of venetoclax to azacitidine improved survival and remission rates in previously untreated adults with acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy (CT), the VIALE-A trial has shown.

Venetoclax-azacitidine duo may benefit older patients with AML

24 Sep 2020

Selpercatinib shows promise in RET-mutant medullary thyroid cancer

24 Sep 2020

Selective RET inhibition with selpercatinib has demonstrated durable efficacy with low-grade toxicity in medullary thyroid cancer patients harbouring RET mutation, according to the results of a phase I–II trial.

Selpercatinib shows promise in RET-mutant medullary thyroid cancer

24 Sep 2020

Exercise seems ineffective to boost bone mineral density while on ADT

23 Sep 2020

Moderate-intensity aerobic and resistance exercises may not be enough to attenuate the negative effects of androgen deprivation therapy (ADT) on metabolic markers and bone mineral density in older men with prostate cancer, a recent study has found.

Exercise seems ineffective to boost bone mineral density while on ADT

23 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

Venetoclax-azacitidine duo may benefit older patients with AML

Venetoclax-azacitidine duo may benefit older patients with AML

Selpercatinib shows promise in RET-mutant medullary thyroid cancer

Selpercatinib shows promise in RET-mutant medullary thyroid cancer

Exercise seems ineffective to boost bone mineral density while on ADT

Exercise seems ineffective to boost bone mineral density while on ADT